GlassScriptPhysician profile
Christopher N Roybal
NPI 1639375397
$51,076.05
in general payments reported to CMS, 2019-2025
24 companies · $7,456 in 2025
The $7,456 reported for 2025 was more than what 94% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $5,520 · 2021: $5,579 · 2022: $4,011 · 2023: $7,932 · 2024: $8,886 · 2025: $7,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Food and Beverage: $3,718 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,800 · Travel and Lodging: $1,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,975.00 |
| Food and Beverage | $3,717.61 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,800.00 |
| Travel and Lodging | $1,781.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $22,147.11 | 2019-2021 | |
| Genentech USA, INC. | $13,045.11 | 2020-2025 | Vabysmo, Susvimo |
| Genentech, INC. | $7,014.40 | 2023 | Vabysmo, Susvimo |
| Abbvie INC. | $2,913.31 | 2022-2025 | Ozurdex |
| Carl Zeiss Meditec USA, INC. | $2,865.81 | 2021-2025 | Atlas 500, Cirrus 6000 With Angioplex, Cirrus Hd-Oct |
| Alcon Vision LLC | $690.14 | 2019-2025 | Constellation |
| Regeneron Healthcare Solutions, INC. | $552.02 | 2019-2025 | Eylea Hd, Eylea |
| Alimera Sciences, INC. | $373.44 | 2024 | Yutiq, Iluvien |
| Apellis Pharmaceuticals, INC. | $358.33 | 2023-2025 | Syfovre |
| Notal Vision, INC. | $268.87 | 2022 | |
| Astellas Pharma US INC | $211.95 | 2023-2025 | Izervay |
| Sun Pharmaceutical Industries INC. | $124.98 | 2022 | |
| Bausch & Lomb Americas INC. | $105.05 | 2022-2025 | Xipere |
| Eyepoint US, INC. | $86.59 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $69.14 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $55.20 | 2021 | |
| Coherus Oncology, INC. | $46.72 | 2022-2023 | |
| Biogen, INC. | $27.29 | 2024 | Byooviz |
| Harrow Eye, LLC | $22.64 | 2025 | Triesence |
| Alcon Research LLC | $20.55 | 2021 | |
| Abbott Laboratories | $20.50 | 2023 | Freestyle Libre 2 |
| Ani Pharmaceuticals, INC. | $19.38 | 2025 | Yutiq |
| Boston Scientific Corporation | $19.35 | 2021 | |
| Spark Therapeutics, INC. | $18.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Roybal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.